Current advancements in cellular immunotherapy for autoimmune disease.

IF 7.9 2区医学 Q1 IMMUNOLOGY

Seminars in Immunopathology Pub Date : 2025-01-16 DOI:10.1007/s00281-024-01034-5

Corbett T Berry, Caitlin S Frazee, Patrick J Herman, Sisi Chen, Anna Chen, Yvonne Kuo, Christoph T Ellebrecht

{"title":"Current advancements in cellular immunotherapy for autoimmune disease.","authors":"Corbett T Berry, Caitlin S Frazee, Patrick J Herman, Sisi Chen, Anna Chen, Yvonne Kuo, Christoph T Ellebrecht","doi":"10.1007/s00281-024-01034-5","DOIUrl":null,"url":null,"abstract":"<p><p>The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach by redirecting immune cells to correct the underlying autoimmunity. This review explores the latest advances in cellular immunotherapies for autoimmune diseases, focusing on various strategies, such as the use of chimeric antigen receptor (CAR) T cells, chimeric auto-antibody receptor (CAAR) T cells, regulatory T cells (Tregs), and tolerogenic dendritic cells (TolDCs). We review recent preclinical studies and results from clinical trials that demonstrate the potential for these therapies to either deplete autoreactive cells or promote immune tolerance through broad or selective targeting of immune cell populations. Key challenges such as ensuring specificity, preventing off-target effects, and improving the longevity of therapeutic effects are discussed. The evolving landscape of cellular immunotherapies holds promise for more durable treatment responses and increased specificity for autoimmune disease treatment.</p>","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"7"},"PeriodicalIF":7.9000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739237/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Immunopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00281-024-01034-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach by redirecting immune cells to correct the underlying autoimmunity. This review explores the latest advances in cellular immunotherapies for autoimmune diseases, focusing on various strategies, such as the use of chimeric antigen receptor (CAR) T cells, chimeric auto-antibody receptor (CAAR) T cells, regulatory T cells (Tregs), and tolerogenic dendritic cells (TolDCs). We review recent preclinical studies and results from clinical trials that demonstrate the potential for these therapies to either deplete autoreactive cells or promote immune tolerance through broad or selective targeting of immune cell populations. Key challenges such as ensuring specificity, preventing off-target effects, and improving the longevity of therapeutic effects are discussed. The evolving landscape of cellular immunotherapies holds promise for more durable treatment responses and increased specificity for autoimmune disease treatment.

查看原文本刊更多论文

自身免疫性疾病细胞免疫治疗的最新进展。

自身免疫性疾病的治疗目前受到很大程度上抑制免疫系统的疗法的限制，通常导致部分和暂时的缓解。细胞免疫疗法通过重定向免疫细胞来纠正潜在的自身免疫提供了一种有针对性的方法。本文综述了细胞免疫治疗自身免疫性疾病的最新进展，重点介绍了嵌合抗原受体（CAR） T细胞、嵌合自身抗体受体（CAAR） T细胞、调节性T细胞（Tregs）和耐受性树突状细胞（TolDCs）的使用等多种治疗策略。我们回顾了最近的临床前研究和临床试验结果，这些研究表明这些疗法可能通过广泛或选择性靶向免疫细胞群来消耗自身反应性细胞或促进免疫耐受。关键的挑战，如确保特异性，防止脱靶效应，并提高治疗效果的寿命进行了讨论。细胞免疫疗法的发展前景为更持久的治疗反应和提高自身免疫性疾病治疗的特异性提供了希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Immunopathology 医学-病理学

CiteScore

19.80

自引率

2.20%

发文量

审稿时长

12 months

期刊介绍： The aim of Seminars in Immunopathology is to bring clinicians and pathologists up-to-date on developments in the field of immunopathology.For this purpose topical issues will be organized usually with the help of a guest editor.Recent developments are summarized in review articles by authors who have personally contributed to the specific topic.